| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8446874 | European Journal of Cancer | 2012 | 10 Pages |
Abstract
Temsirolimus administered weekly at the dose of 75Â mg/m2 did not meet the primary objective efficacy threshold in children with high-grade glioma, neuroblastoma or rhabdomyosarcoma; however, meaningful prolonged stable disease merits further evaluation in combination therapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Birgit Geoerger, Mark W. Kieran, Stephan Grupp, Danuta Perek, Jill Clancy, Mizue Krygowski, Revathi Ananthakrishnan, Joseph P. Boni, Anna Berkenblit, Sheri L. Spunt,